Coupling of inflammatory cytokine signaling pathways probed by measurements of extracellular acidification rate.
There is a growing interest in the mechanisms of how cells integrate the multitude of signals that emanate during inflammatory stimuli, such as the hepatic acute phase response to burn or trauma. We have used measurements of extracellular acidification rate (ECAR) of HepG2 cells cultured on microporous membranes to probe the coupling between signaling pathways for gp130 family cytokines (interleukin-6, oncostatin M) and IL-1, each of which is considered to play a significant role in the hepatic acute phase response. We found that brief (30 min or less) exposure to any of these cytokines desensitized the HepG2 cells to subsequent exposure with the same cytokine. Furthermore, we found that this property serves as a probe of the coupling of signaling pathways: exposure to IL-1 did not desensitize the cells to exposure to OSM and vice versa. However, cells exposed to IL-6 with soluble gp80, which together share with OSM the use of gp130 as a signal transducing receptor, were subsequently unable to respond to OSM, and vice versa. Simultaneous exposure of cells to moderate concentrations (near their respective EC50 values) of both IL-1 and OSM resulted in synergistic effects on the ECAR, but simultaneous exposure to saturating concentrations of IL-1 and OSM resulted in a response that tracked that of OSM alone. These results suggest that the signaling pathways of IL-1 and OSM may be simultaneously activated in HepG2 cells under moderate inflammatory cytokine challenge but that the cells must prioritize their response under extreme cytokine challenges.
Center for Engineering in Medicine and Surgical Sercices, Massachusetts General Hospital, Harvard Medical School, Boston 02114-2696, USA. cmroth@rci.rutgers.edu
C M
CM
Roth
R L
RL
Kohen
S P
SP
Walton
M L
ML
Yarmush
D000143:Acids / Q000737:chemistry*; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D005110:Extracellular Space / Q000737:chemistry; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D015850:Interleukin-6 / Q000494:pharmacology*; D053683:Oncostatin M; D010455:Peptides / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects*
D000143:Acids; D007375:Interleukin-1; D015850:Interleukin-6; C508351:OSM protein, human; D010455:Peptides; D053683:Oncostatin M